1. Chapter 3 Pharmacokinetics 药物代谢动力学 Part II Basic pharmacokinetic variables

2. 1 Concentration-time curve

3. Basic variables 1.1 Area under the curve, AUC 药物浓度-时间曲线下面积
Pharmacokinetic indication:
The amount of drugs enters systemic circulation

4. 1.2 Peak time, (Tmax, 药物浓度达峰时间)
Pharmacokinetic indication:
The speed of drugs enters systemic circulation

5. 1.3 Peak concentration (Cmax, 药物峰浓度)
Pharmacokinetic indication:
The maximum concentration of drugs exposed to systemic circulation

6. 2 Variables for ADME
2.1 For Absorption
Bioavailability (生物利用度, F)
Definition:
The fraction of unchanged drug reaching the systemic circulation following administration by any route .
吸收入体循环的药量 F=
×100%
给药量

7. Routes of Administration, Bioavailability, and General Characteristics

8. For a drug administered orally
F=Fab·FI·FH

9. Factors influencing bioavailability
Physical properties of the drug (hydrophobicity疏水性, pKa, solubility); The drug formulation; Whether the formulation is administered in a fed or fasted state; Gastric emptying rate/Health of the GI tract; Interactions with other drugs/foods; Disease states affecting liver metabolism or gastrointestinal function; Individual variation in metabolic differences

10. Apparent volume of distribution (Vd,表观分布容积)
2.2 For Distribution
Apparent volume of distribution (Vd,表观分布容积)
Definition:
The amount of drug in the body to the concentration of drug (C) in the blood.
Vd=D/C
D: drug in the body (mg or mg/kg）
C: blood concentration（mg/L）

11. Pharmacokinetic indication:
A drug's volume of distribution reflects the extent to which it is present in extravascular tissues and not in the plasma
Vd<5L: drug restricted to the vasculature[‘væskjulitʃə(r] 脉管系统
Vd L: drug restricted to the extracellular fluid;
Vd>40 L: drug distributes to the total body water;
Vd>100 L: drug accumulates in certain tissues.

12. 2.3 For elimination 2.3.1 Types of elimination Kinetic order （动力学级别）
Zero-order kinetics（零级动力学, 恒量消除)
First-order kinetics (一级动力学, 恒比消除, 大多数药物)
Mixed elimination kinetics (混合型消除）

13. 2.3.2 Elimination half-life (t1/2, 消除半衰期）
The time taken for the plasma drug concentration to fall to half of its value.
消除相半衰期: 血药浓度下降一半需要的时间.
T1/2=0.693/K（一级动力学消除药物）
K：消除速率常数

14. Elimination half-life is important for the design and optimization of dosage regimens
1) Helpful to predict when could the drug totally be eliminated from the body (5 t1/2) ;
2) Helpful to design the dosing interval (t1/2);
3) Helpful to predict when could the drug reach steady state plasma concentration (稳态血药浓度) in repetitive dosing regimens (5 t1/2) .

15. 3 Repetitive dosing
3.1 Dose regimen 1: equal amount & equal interval (t1/2)
Concentration time curve
Steady state plasma concentration (稳态血药浓度, Css)
Refers to the steady-state plasma concentration of drug when the overall intake of the drug is fairly in dynamic equilibrium with its elimination.

16. 3.2 Dose regimen 2: loading dose & maintenance dose
Concentration time curve

17. Supplementary reading
Following administration of a dose of drug, onset of the effect is preceded by a lag period, after which the magnitude of the effect increases to a maximum and then declines; if a further dose is not administered, the effect eventually disappears as the drug is eliminated. This time course reflects changes in the drug's concentration as determined by the pharmacokinetics of its absorption, distribution, and elimination. Accordingly, the intensity of a drug's effect is related to its concentration above a minimum effective concentration, whereas the duration of this effect reflects the length of time the drug level is above this value. These considerations, in general, apply to both desired and undesired (adverse) drug effects, and as a result, a therapeutic window exists reflecting a concentration range that provides efficacy without unacceptable toxicity. Similar considerations apply after multiple dosing associated with long-term therapy, and they determine the amount and frequency of drug administration to achieve an optimal therapeutic effect. In general, the lower limit of the therapeutic range appears to be approximately equal to the drug concentration that produces about half the greatest possible therapeutic effect, and the upper limit of the therapeutic range is such that no more than 5% to 10% of patients will experience a toxic effect. For some drugs, this may mean that the upper limit of the range is no more than twice the lower limit. Of course, some patients may benefit greatly from drug concentrations that exceed the therapeutic range, whereas others may suffer significant toxicity at much lower values (e.g., digoxin).

18. 大纲要求
半衰期的定义，影响半衰期的因素;
消除类型、坪值、生物利用度。

19. Glossary
Pharmacokinetic variables Concentration-time curve Area under the curve, AUC Bioavailability Apparent volume of distribution Elimination half-life (t1/2) Dose regimen Loading dose/maintenance dose